Grace Therapeutics (NASDAQ:GRCE) Receives “Buy” Rating from HC Wainwright

Grace Therapeutics (NASDAQ:GRCE)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 247.83% from the stock’s current price.

Grace Therapeutics Stock Performance

Shares of NASDAQ:GRCE opened at $3.45 on Tuesday. The stock has a market capitalization of $34.98 million, a P/E ratio of -3.42 and a beta of 1.36. The firm has a fifty day simple moving average of $3.69. Grace Therapeutics has a 52 week low of $2.13 and a 52 week high of $4.97.

Grace Therapeutics (NASDAQ:GRCE) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. Research analysts forecast that Grace Therapeutics will post -0.98 earnings per share for the current year.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.